Our Work
Latham Advises on £133.4 Million Placing by Dechra Pharmaceuticals
June 9, 2020
London equity capital markets team represents Investec in placing by veterinary products developer.
Latham & Watkins advised Investec as the sole bookrunner on a £133.4 million cash placing by Dechra Pharmaceuticals PLC (Dechra), an international veterinary pharmaceuticals and related products business. The placing represents approximately 5% of Dechra’s previously issued share capital.
The transaction builds on Latham’s significant equity capital markets activity in London over the past two months as many London listed companies seek to raise equity.
Latham’s team was led by London corporate partner Chris Horton, with associates Sean Meehan and Frederick Gardner. Partner Ryan Benedict and associate Sarah Youssefi advised on US securities law matters.